4-Thiazolidinones: a novel class of hepatitis C virus NS5B polymerase inhibitors


Kaushik-Basu N., Bopda-Waffo A., Talele T. T. , Basu A., Chen Y., KÜÇÜKGÜZEL Ş. G.

FRONTIERS IN BIOSCIENCE, vol.13, pp.3857-3868, 2008 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13
  • Publication Date: 2008
  • Doi Number: 10.2741/2974
  • Title of Journal : FRONTIERS IN BIOSCIENCE
  • Page Numbers: pp.3857-3868

Abstract

In a quest to identify novel compounds targeting HCV viral replicase, we evaluated a new series of 4-thiazolidinone derivatives (18 compounds). Our in vitro NS5B RdRp inhibition analysis with a series of 2', 4'-difluoro-4-hydroxybiphenyl- 3-carboxylic acid [2-(5-nitro-2- furyl/substituted phenyl)-4-thiazolidinone-3-yl] amides (1-7) yielded IC50 values ranging between 45-75 microM. Of these, lead compound 6: 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid[2-(2-fluorophenyl)-4-thiazolidinone- 3-yl] amide exhibited an IC50 value of 48 microM and inhibited NS5B non-competitively with respect to UTP and exhibited a mixed mode of inhibition with respect to RNA. Molecular docking of thiazolidinone derivatives within the allosteric site of NS5B yielded significant correlation between their calculated binding affinity and IC50 values. Taken together, these data suggest that the 4-thiazolidinone scaffold may be optimized for generating new analogues with improved anti-NS5B potency.